Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Lucentis (ranibizumab) in acute central serous chorioretinopathy
2010-020902-13Phase 2Terminated
- Sponsor
- Department of Ophthalmology, Medical University of Vienna
- Start
- May 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ranibizumab in Central Serous Chorioretinopathy (CSCR), sponsored by Department of Ophthalmology, Medical University of Vienna. Primary endpoint: Resolution of neurosensory detachment in OCT. Started May 2011; status: terminated.
02
Drugs
ranibizumab
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on 2010-020902-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020902-13.